SLC5A2 and hydrops fetalis: Furthermore, choosing the optimal device type may be further complicated by the concurrent use of HF medications (e.g., angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors), which can also independently reduce the incidence of SCD42.